Last reviewed · How we verify
IBR900 cell injection
At a glance
| Generic name | IBR900 cell injection |
|---|---|
| Sponsor | Imbioray (Hangzhou) Biomedicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma (PHASE1)
- A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors (EARLY_PHASE1)
- IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IBR900 cell injection CI brief — competitive landscape report
- IBR900 cell injection updates RSS · CI watch RSS
- Imbioray (Hangzhou) Biomedicine Co., Ltd. portfolio CI